Mexico Pharmaceuticals & Healthcare Report Q2 2015

Jan 26, 2015 - Business Monitor International - 133 pages - USD $1,295
Abstract Table of Contents Request Details Related
Increased trade activity will promote growth in Mexico's pharmaceutical a nd healthcare markets in 2015. In particular, generic medicine will continue to grow over the forecast period, accounting for a larger percentage of total pharmaceutical spending. Indeed, the country will continue to see positive changes as government regulations improve industry appeal to foreign drugmakers.

Headline Expenditure Projections
  • Pharmaceuticals: MXN185bn (USD14bn) in 2014 to MXN192bn (USD15bn) in 2015; +7.2% in local currency terms and +5.8% in US dollar terms. Forecast increased from Q115 due to revised historical data.
  • Healthcare: MXN1,124bn (USD85bn) in 2014 to MXN1,1214bn (USD91bn) in 2015; +8.0% in local currency terms and +6.6% in US dollar terms. Forecast increased from Q115 due to revised historical data.
Risk/Reward Index

Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Index (RRI), making it the fifth-most attractive pharmaceutical market in the region.

Key Trends And Developments

January 2015
  • Mexico's National Strategy for Prevention and Control of Overweight, Obesity and Diabetes published results that in 2014, their program was successful in decreasing mortality rates of diabetes by 1% and cardiovascular disease by 2.6%.
  • COFEPRIS (Federal Commission for the Protection against Sanitary Risk) reported having removed more than 119,000 pharmaceutical advertisements throughout 2014. The ads, which were considered to be irregular, accrued more than MXN70mn (USD5mn) in fines.
December 2014
  • Mexico became the largest exporter of pharmaceutical products in Latin America with its pharmaceutical industry accounting for 1.2% of its gross domestic product.
  • The Mexican government made the largest purchase of pharmaceuticals in the history of the public sector, spending MXN51bn (USD3.5bn) on imported medicines for 2015. The figure is MXN8bn (549mn) more than the previous year.
BMI Economic View: Mexico's current account deficit...

The Mexico Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Mexico Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Mexico pharmaceutical and healthcare industry.

Key Benefits
  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Mexico, to test other views - a key input for successful budgeting and strategic business planning in the Mexican pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Mexican pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Mexico.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

Order This Report
FORMAT: PDF - Download Now with 3 Quarterly Updates $1,295 USD
LICENSE: Single-User
DELIVERY: Instant Download

Once you’ve found the right report, click ‘order now’ and complete the checkout process using any major credit card, check or wire/bank transfer.

Need multi-user or enterprise license pricing? Contact us for a custom quote!
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away

About the Publisher
BMI Research offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities. Through 'Total Analysis,' their unique, reflexive approach linking macroeconomic, industry and financial market analysis, they help clients gain unparalleled insight across 24 industries and 200 global markets.